Taxol Articles
Medigene slashes staff in profitability drive
30 September 2010
Market for paclitaxel injection in China worth $67 million
24 August 2010
Novelos shares slump 82% as pivotal Ph III lung cancer trial fails to meet primary survival endpoint
25 February 2010
Spectrum Pharma licenses lymphoma drug belinostat from TopoTarget for up to $350 million
3 February 2010
Pfizer drops figitumumab in NSCLC on disappointing Ph III; FDA delays Prevnar 13 and rejects Basilea/J&J’s ceftobiprole for cSSSI
4 January 2010
US FDA clears restart of Roche Ph III Avastin trials; other strong data presented at San Antonio meeting
14 December 2009
Phyton Biotech acquires assets of Natural Pharmaceuticals
13 October 2009
Pfizer halts Sutent Ph III breast cancer study
3 June 2009
Avastin boosts PFS 36% in HER2-negative patients
1 June 2009
Wyeth presents strong combo drug data at ASCO
29 May 2009
Novartis buys generics cancer firm for $1.2B
20 May 2009
FDA accuses Sanofi of using misleading article
15 May 2009
Bayer and Onyx halt Nexavar trial
28 April 2009
Abraxane rights cost deepens Abraxis' loss
16 March 2009
Synta suspends SYMMETRY trial
9 March 2009
Boston Sci's Taxus Liberte debuts in Japan
9 March 2009
Cell Thera sells Zevalin to partner Spectrum
2 March 2009
Synta gets $10M milestone from GSK under elesclomol accord
23 February 2009
Amgen/Takeda resume motesanib development
23 February 2009
Peregrine's Ph II breast cancer drug meets first-stage endpoint
16 February 2009
Abraxane launched in Germany
9 February 2009
Genta begins trials for novel oral taxane
19 January 2009
Immutep drug doubles breast cancer response
12 January 2009
Abraxis launches Abraxane in EU
22 December 2008
18% of BC patients see complete response with Abraxane regimen
22 December 2008
Novartis' Afinitor may overcome Herceptin resistance; Ph I study
22 December 2008
Abraxis seeks to reacquire US Abraxane marketing rights from AZ
1 December 2008
Ph III motesanib trial suspended on deaths
1 December 2008
Japan stock market week to Nov 24, 2008
1 December 2008
EntreMed achieves endpoint in NSCLC study
17 November 2008
New therapy may stop pancreatic tumor growth
3 November 2008
Peregrine fully enrolled for Ph II NSCLC trial
27 October 2008
Abraxane gains marketing OK in Australia
27 October 2008
Boston Scientific presents new TAXUS data
20 October 2008
NCCN to test Abraxane for SPARC benefits
13 October 2008
Strong mid-stage data on Pfizer's NSCLC drug
22 September 2008
High response rate with TopoTarget's BelCaP
15 September 2008
OncoGenex licences Tocosol to Eagle
8 September 2008
PCI with Taxus stent compares well to CABG
8 September 2008
Oncolytics takes Reolysin into Ph II
8 September 2008
HGS completes enrollment in Ph II mapatumumab trial
1 September 2008
Elesclomol drives cell death by inducing ROS
1 September 2008
Peregrine initiates Ph II bavituximab study
18 August 2008
Biocon/Abraxis debut Abraxane in India
28 July 2008
Angiotech wins patent appeal in UK high court
21 July 2008
Opaxio misses primary endpoint in Ph III study
14 July 2008
Abbott Labs' Xience V launched in the USA
14 July 2008
Abraxis to appeal ruling on Elan patent
23 June 2008
GSK/Synta's elesclomol good in Ph II
26 May 2008
Abbott reports two-year data for Xience V
19 May 2008
GSK's Tykerb enters Ph III breast cancer trial
19 May 2008
Abraxis reports Phase I results for Abraxane
28 April 2008
India's Dabur goes to Fresenius for $220M
28 April 2008
Antisoma starts Ph III NSCLC trial, earns $25M
21 April 2008
Reolysin fares well in early carcinoma trial
21 April 2008
Cook Medical's Zilver PTX stent used in NZ
14 April 2008
Taiho submits Japanese NDA for Abraxis BioSci's Abraxane
24 March 2008
Japan stock market week to March 17, 2008
24 March 2008
Barr's Pliva subsid gets FDA OK for generic Taxol
17 March 2008
Avastin to become new standard for HER2 MBC
17 March 2008
CT submits Xyotax MAA to EMEA
10 March 2008
UPDATE: Bayer and Onyx halt Nexavar trial in NSCLC
25 February 2008
Avastin improves PFS in breast cancer
25 February 2008
Bayer/Onyx halt Nexavar trial in NSCLC
25 February 2008
FDA makes elesclomol orphan for melanoma
4 February 2008
Peregrine gets Indian OK for Ph II NSCLC trial
28 January 2008
OXiGENE's Zybrestat achieves endpoints in ovarian cancer
7 January 2008
Avastin shows good safety profile in Ph II breast cancer trial
24 December 2007
Synta gets $80M upfront payment from GSK
10 December 2007
ODAC
10 December 2007
Orion signs Nordic distribution for Oasmia's Paclical
10 December 2007
Strong early data for ImmuFact IMP321 in breast cancer
3 December 2007
Abraxis licenses Abraxane to Green Cross for Korea
3 December 2007
Belinostat shows promise in range of cancer indications
5 November 2007
Abraxane gets CHMP nod for breast cancer
29 October 2007
Stock Commentary - Europe - week to Oct 1, 2007
8 October 2007
Stock Commentary - New York week to Sept 10, 2007
17 September 2007
Ph II NSCLC ASA404 trial supports earlier findings
17 September 2007
World Conference on Lung Cancer highlights important developments
17 September 2007
Aranesp has no negative survival impact in SCLC
17 September 2007
Potential of Peregrine's bavituximab and radiation confirmed
10 September 2007
Five-year data indicate Taxus stent's safety and efficacy
10 September 2007
OVATUREtrial.com drug trial web site launched
10 September 2007
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
